diabetes-drug

Diana Zuckerman is the president of the National Research Center for Women & Families. After serving on the faculty of Vassar
While data from the three studies appears to show a comforting safety profile, dulaglutide will be under intense scrutiny
Last October, Eli Lilly released data showing dulaglutide lowered hemoglobin A1c levels more than twice-daily injections
Researchers found in their analysis that torcetrapib, a kind of CETP inhibitor, raised good cholesterol levels and lowered